Navigation Links
FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Date:4/23/2008

Within the First Eight Months Since its Introduction in the United States,

VYVANSE has Achieved Over One Million Prescriptions In a Clinical Study With Adults, VYVANSE was Shown to Significantly Improve

the Symptoms of ADHD (Inattention, Hyperactivity and Impulsivity)(1)

BASINGSTOKE, England and PHILADELPHIA, April 23 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP) (NASDAQ: SHPGY,), the global specialty biopharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE(TM) (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. VYVANSE, introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years, is now the first and only once-daily prodrug stimulant approved to treat adults with ADHD. In its first eight months of availability, more than one million VYVANSE prescriptions have been filled.(2)

"We are very pleased with this FDA approval of the adult indication for VYVANSE," said Matthew Emmens, Chief Executive Officer of Shire. "This approval provides physicians a new treatment option that can help their adult patients by significantly improving their ADHD symptoms. VYVANSE has been well accepted by the medical community. With Shire's experience as a leader in the development and commercialization of ADHD medications, we are confident that this approval for adult patients will help continue to increase prescription share and volume of VYVANSE."

"Many people may think of ADHD as only a childhood disorder but the fact is that the majority of children diagnosed with ADHD still have symptoms as an adult. These symptoms can significantly impact them at work, home and in relationships, where they have important responsibilities," said David W. Goodman, assistant professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine and director of the Adult Attention
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
2. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
3. Medicare Approves in Home Sleep Apnea Testing
4. 3SBio Inc. Approves Share Repurchase Program
5. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
6. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
7. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
8. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
9. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
10. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
(Date:9/17/2014)... 17, 2014 Beckman Coulter , ... and healthcare, has renewed its agreement with Personify ... of the agreement, Personify will continue to streamline the ... on recruitment analytics, including time-to-fill, time-to-source and a deep ... agreement with Personify was based on the success of ...
(Date:9/17/2014)... Scotland , September 17, 2014 /PRNewswire/ ... new mode of action from a truly ... decade  MGB Biopharma, a biopharmaceutical ... anti-infectives, announces today that it has secured ... its lead antibacterial, MGB-BP-3, against a range ...
(Date:9/17/2014)... Wilmington, DE (PRWEB) September 17, 2014 ... profit organization committed to lowering the barriers to ... has announced the appointment of Carmen Nitsche as ... organization looks to expand its global reach. , ... she was Vice President, Corporate Development. At Accelrys, ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... , ATLANTA, Sept. 14 CryoLife, Inc. ... medical device and cardiovascular tissue processing company, announced today that it ... Conference at the Grand Hyatt New York in New York City. ... executive officer of CryoLife, Inc., will present Monday, September 21 at ...
... , NATICK, Mass., Sept. ... ) today announced that it has entered into a ... company offering advanced testing solutions for urinary incontinence. ... combines staffing, equipment, supplies and results analysis, helping to ...
... , HOLDEN, Mass., Sept. ... appointment of Elkan Gamzu, Ph.D. as Chairman to its ... years of pharmaceutical and biotechnology experience and has held ... President of Project Management at Millenium Pharmaceuticals, CEO of ...
Cached Biology Technology:CryoLife to Present at UBS Global Life Sciences Conference 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 2Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network 3Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics' Board of Directors as Chair 2
(Date:9/17/2014)... "Nature has developed, very cleverly, some lessons on how ... design," said Joseph Shaw, director of the Optical Technology ... and structures at the nanoscale, we,ll discover them." , ... in August during a conference called "The Nature of ... Liang of the University of Arizona College of Optical ...
(Date:9/17/2014)... New research from the Copenhagen Centre for Social Evolution ... evolutionary theory that birth weight and -length can partially ... disorders such as autism and schizophrenia later in life. ... births, and subsequent hospital diagnoses for up to 30 ... factors. The study is published today in the ...
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2
... of the Santa Cruz Mountains two closely related species of ... very different social lives. The California mouse ( Peromyscus californicus ... mouse ( Peromyscus maniculatus ) is sexually promiscuous. Researchers ... differences in sexual behavior impact the bacteria hosted by each ...
... toward helping people grow big, strong muscles without needing to ... blocking the function of a protein called Grb10 while mice ... muscular than their normal counterparts. This discovery appears in the ... . Outside of aesthetics, this study has important implications for ...
... to common environmental chemicals - polyfluoroalkyl compounds (PFCs) - ... at 20 months of age, according to a study ... online in the August 30 edition of Environmental ... production of fluoropolymers and are found widely in protective ...
Cached Biology News:Monogamy and the immune system 2Monogamy and the immune system 3Monogamy and the immune system 4Monogamy and the immune system 5'Hulk' protein, Grb10, controls muscle growth 2Chemical exposure in the womb from household items may contribute to obesity 2
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
... measurements in an easy-to-use benchtop package. ... spectrometer (ESI-oa-TOF) concentrates the performance of ... which fits on your bench. The ... 10,000 FWHM and mass accuracy of ...
... Cellular uptake of long double stranded ... RNA interference in a diverse group of ... culture. RNA interference leads to the inhibition ... destruction of the target messenger RNA (mRNA). ...
... and Bruker BioSpins Metabolic Profiler is ... and analysis of complex mixtures. It ... optional Avance NMR spectrometer and integrated ... statistical analysis for applications like:,Assessment of ...
Biology Products: